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Abstract
Rationale: Rhinoviruses (RVs) are major triggers of common cold
and acute asthma exacerbations. RV species A, B, and C may have
distinct clinical impact; however, little is known regarding RV
species–speciﬁc antibody responses in health and asthma.
Objectives: To describe and compare total and RV species–speciﬁc
antibody levels in healthy children and children with asthma, away
from an acute event.
Methods: Serum samples from 163 preschool children with mild
to moderate asthma and 72 healthy control subjects from the
multinational Predicta cohort were analyzed using the recently
developed PreDicta RV antibody chip.
Measurements andMainResults:RV antibody levels varied, with
RV-C and RV-A being higher than RV-B in both groups. Compared
with control subjects, asthma was characterized by signiﬁcantly
higher levels of antibodies to RV-A and RV-C, but not RV-B.
RV antibody levels positively correlated with the number of
common colds over the previous year in healthy children, and
wheeze episodes in children with asthma. Antibody levels also
positively correlated with asthma severity but not with current
asthma control.
Conclusions: The variable humoral response to RV species in
both groups suggests a differential infectivity pattern between
RV species. In healthy preschoolers, RV antibodies accumulate
with colds. In asthma, RV-A and RV-C antibodies are much
higher and further increase with disease severity and wheeze
episodes. Higher antibody levels in asthma may be caused by a
compromised innate immune response, leading to increased
exposure of the adaptive immune response to the virus. Importantly,
there is no apparent protection with increasing levels of antibodies.
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Asthma is a major contemporary epidemic
(1). A considerable proportion of the
asthma burden is attributed to acute
exacerbations, which almost invariably (2)
follow an upper respiratory tract infection
(URI), most often caused by rhinoviruses
(RVs) (3, 4). In addition to exacerbations,
RVs promote asthma in multiple ways
(5–7). Persons with asthma are more
susceptible to symptomatic RV infection
and a suboptimal antiviral response is
associated with increased viral replication
and cytotoxicity (8).
There are 81 RV-A, 33 RV-B, and 33
RV-C full genome sequences available in
addition to 358 yet unclassiﬁed partial
sequences (NCBI Taxonomy Browser). RV-C
genotypes are more diverse than RV-A or
RV-B (9) and recombination is frequent
(10), especially for RV-A and RV-C species
(11). RV species are widespread and
continuously cocirculating throughout the
world (12). RV-A and RV-C species are
associated with severe infections and
hospitalization in young children, especially
those with asthma (13, 14).
After an RV infection, serum
neutralizing antibody titers increase for
about a year and high preexisting
neutralizing antibody titers have been
associated with resistance to reinfection
(15). RV species–speciﬁc and cross-reactive
signal can be deﬁned (16), although
antibody responses against RV-A and RV-C
species are highly cross-reactive. There is
low correlation between the RV genotype
detected during a symptomatic or
recovering period and RV antibody titers
(17–19), possibly because of the high
sequence homology observed between RV
species. Thus, understanding the full extent
of RV epitope diversity is required to
develop a vaccine with wide species
coverage (20).
During an exacerbation, children with
asthma have higher total anti-RV antibody
titers than children without asthma (17) and
RV VP1–speciﬁc IgG1 levels tend to be
higher in adults with asthma than healthy
control subjects, before an experimental
infection (21). Although it has been
suggested that the immune response to RV-C
species is less efﬁcacious than RV-A and
RV-B (17, 21), T-cell responses to RV-A
and RV-C are of similar magnitude (22).
With advancing technology and an
increasing number of sequences available,
we are now able to identify species-speciﬁc
antibodies with increased resolution. In this
study, we take advantage of our recently
developed PreDicta RV chip to describe RV
species–speciﬁc antibody responses in
preschool-age children with or without
asthma.
Methods
Study Population
The PreDicta pediatric cohort is a 2-year
prospective multicenter study, part of the
EU FP7 program PreDicta, and has been
described elsewhere (23). We have analyzed
available serum samples from 163 children,
4–6 years of age, with a diagnosis of mild to
moderate severity asthma conﬁrmed by a
doctor of the participating study center
using prespeciﬁed criteria. Seventy-two
healthy children of matched age, with no
history of asthma/wheeze, served as cross-
sectional control subjects (see Table E1 in
the online supplement). The study was
approved by all participants’ institutional
ethics committees, and written informed
consent was obtained from all parents.
Chip-based Measurement of
RV-Speciﬁc Antibody Levels in
Human Serum Samples
Serum RV-speciﬁc antibody levels were
measured using the newly developed
PreDicta RV chip (19). Brieﬂy, the PreDicta
microarray contains 130 synthesized linear
RV peptides and proteins including 20
recombinant RV capsid proteins, VP1-VP4,
and 15 recombinant VP1 fragments from
ﬁve representative RV strains (RV89, RV14,
RV16, RV2, and RVC). In addition, it also
contains ﬁve recombinant nonstructural
proteins from RV89. Details on the chip-
based measurement of RV-speciﬁc
antibody levels in human serum samples
are provided in the online supplement.
Noise Reduction and Determination
of Peptide Speciﬁcity
Before comparing measurements between
groups, the data were processed to exclude
noninformative signal and determine the
speciﬁcity of peptide signal toward RV-A, -B,
and -C (see Figures E1–E4). The ﬁnal
dataset included antibody signals from RV-A
(n = 14), RV-B (n = 9), and RV-C (n = 2)
species–speciﬁc peptides (see Figure E4 and
Table E2). A detailed description of the
analysis can be found in the online
supplement.
Signiﬁcance Tests
A detailed description of the analysis can be
found in the online supplement.
Results
Differential Antibody Levels against
RV-A, -B, and -C
In the overall population, RV-A (95%
conﬁdence interval [CI], 1.646–1.728)– and
RV-C (95% CI, 1.748–1.845)–speciﬁc signal
levels were signiﬁcantly higher than RV-B
(95% CI, 1.123–1.248) (Figure 1A). This
was the case in both healthy control
children (RV-A 95% CI, 1.518–1.669; RV-C
95% CI, 1.577–1.753; RV-B 95% CI,
1.054–1.298) (Figure 1B) and patients with
asthma (RV-A 95% CI, 1.679–1.776; RV-C
95% CI, 1.797–1.911; RV-B 95% CI,
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Knowledge on the
rhinovirus (RV) species–speciﬁc
antibody response is limited mostly
because of the great phylogenetic
diversity of the virus. Although it has
been suggested that the immune
response to RV-C species is less
efﬁcacious than RV-A and RV-B,
T-cell responses to RV-A and RV-C
can be of similar magnitude.
Moreover, there is only a small
number of studies that describe
antibody accumulation in response to
RV in patients with asthma where a
defective immune response has been
reported.
What This Study Adds to the
Field: A novel RV antibody chip was
used that allows the measurement of
130 different RV proteins and peptides.
Our data suggest that preschool
children with asthma have
accumulated high antibody levels since
a younger age (,3 yr) but with no
apparent protection and they probably
expand their RV repertoire only after
more severe infections, associated with
wheeze. The heightened antibody
levels in asthma suggest a compromised
innate immune response, leading to
increased exposure of the adaptive
immune response to the virus.
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1.116–1.262) (Figure 1C). Moreover, in
the asthma group and in the overall
population, RV-C–speciﬁc antibody signal
was higher than that to RV-A (Figures 1A
and 1C).
Children with asthma have higher RV-A
and RV-C, but not RV-B, antibody levels
than healthy control subjects. The average
RV antibody signal was signiﬁcantly higher
in patients with asthma (95% CI,
1.457–1.543) than healthy participants
(95% CI, 1.342–1.468) (Figure 2A). When
analyzed individually, the average RV-A
(Figure 2B) and RV-C (Figure 2D)
species–speciﬁc signals were signiﬁcantly
higher in asthma (RV-A 95% CI,
1.679–1.776; RV-C 95% CI, 1.797–1.911)
than control subjects (RV-A 95% CI,
1.518–1.669; RV-C 95% CI, 1.577–1.753),
whereas no differences were observed for
RV-B (Figure 2C). Signiﬁcant differences
between the asthma and control groups
were also found for the peptides identifying
both RV-A and RV-C (RV-A/C; P =
0.0089) and those identifying all RV species
(RV-A/B/C; P = 0.0014) but not those
identifying RV-A and RV-B (RV-A/B;
P = 0.4137).
Participants were grouped (K = 2,
unsupervised K-means clustering) based
on the measured RV species–speciﬁc and
mixed antibody signal into high and low
responders. Signiﬁcantly more patients with
asthma were classiﬁed as high responders
when compared with healthy donors, but
only for the RV-A–speciﬁc (Figure 2E),
RV-C–speciﬁc (Figure 2F), and RV-A/C
peptides (Figure 2G). Regression analysis
suggested that patients with asthma
were signiﬁcantly more likely to be high
responders to RV-A (95% CI, 0.233–0.775)
and RV-C (95% CI, 0.199–0.661)
species–speciﬁc and RV-A/C (95% CI,
0.169–0.716) mixed-signal peptide
measurements. No differences were
observed in groups of high and low
responders to RV-B–speciﬁc, RV-A/B, and
RV-A/B/C mixed peptides.
RV antibody levels reﬂect the number
of URIs in the last 12 months in healthy
children but not in patients with asthma.
Linear regression was used to investigate the
relationship between RV antibody signal
and number of reported URIs for a time
window of 12months before inclusion in the
study (Figure 3). URI data were available
for 64 of 72 healthy donors and 160 of
163 patients with asthma. RV antibody
signal increased linearly with the number
of reported URIs in healthy donors
(Figure 3A), but not in patients with
asthma (Figure 3E). This was observed in
all RV species (Figures 3B–3D and 3F–3H).
Patients with asthma who reported no or
few URIs during the last 12 months had RV
antibody signals at the same level as healthy
patients with multiple URIs (see Figure E5).
Moreover, patients with asthma reporting
no URIs (mean, 1.650; SD, 0.18) during
the past year exhibited signiﬁcantly higher
P = 0.0001) RV antibody signal than
healthy donors with no history of URIs
(mean, 1.036; SD, 0.04).
Association between RV Antibody
Levels and Lower Respiratory
Infections
Donors were grouped based on the number
of lower respiratory infections (LRIs; LRI =
0 and LRI. 1). In healthy participants,
only RV-B–speciﬁc antibody levels were
signiﬁcantly lower (unpaired Student’s t test
with Welch correction, P = 0.0269) in
children with more than one LRI in the
previous year (mean, 0.7449; SEM6 0.155;
n = 6) compared with children with no
reported LRIs (mean, 1.216; SEM6
0.07052; n = 58). RV-A–speciﬁc antibody
levels were elevated in children with no
LRIs (mean, 1.616; SEM6 0.03916; n = 58)
compared with children with more than
one LRI (1.4336 0.1418; n = 6) but did
not reach statistical signiﬁcance. No
differences were observed in patients
with asthma.
Association between RV Antibody
Levels and Susceptibility to the
Spread of URIs to the Lower
Respiratory Tract
We have performed nonparametric
correlation of the number of URIs (mean,
5.762; SEM6 0.304) and LRIs (mean,
1.306; SEM6 0.193) in the asthma group
(n = 160) using Spearman test. The
variables were negatively correlated (r =
20.280; P = 0.000). We explored the effect
of RV antibody levels on the URIs versus
LRIs correlation. RV-A antibody levels as
a cofactor did not affect the negative
correlation (r =20.321; P = 0.000). The
same applied for RV-B antibody levels
(r =20.325; P = 0.000) and RV-C
(r =20.326; P = 0.000). Age did not
affect the negative correlation (r =20.315;
P = 0.000). In the healthy group (n = 64)
the correlation between URIs (mean, 4.109;
SEM6 0.335) and LRIs (mean, 0.109;
SEM6 0.045) was not signiﬁcant
(r = 20.158; P = 0.212).
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Figure 1. Rhinovirus (RV) species–specific antibody signal levels in preschool children with and without asthma. (A) In all participants of the study, the
highest RV (HRV) signal is observed against RV-C peptides followed by RV-A and RV-B antibody levels. (B) In healthy donors, RV-A and RV-C signals were
higher than RV-B. (C) In patients with asthma, the HRV antibody signal is observed against RV-C peptides followed by RV-A and RV-B. Differences are
significant at the 0.05 level using ANOVA and post hoc Tukey test.
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In children with asthma, RV-A and RV-C,
but not RV-B, antibody levels positively
correlate with the number of asthma-related
episodes. The relation of RV antibody levels
and the reported events of lower respiratory
symptomatology for the past 12 months
were investigated (Figure 4). Data regarding
the number of respiratory episodes were
available for 160 out of 163 patients with
asthma. The RV-A (Figure 4B)– and RV-C
(Figure 4D)–speciﬁc signal were positively
correlated with the number of wheeze
episodes. The correlations were not affected
by the number of reported URIs.
Correlation of RV Antibody Levels
with Asthma Severity
Children with asthma were characterized by
the clinical investigators as intermittent
(n = 47) or persistent (n = 115) (GINA).
Higher RV antibody signal levels were
present in children with persistent asthma
(95% CI, 1.486–1.591) than in children with
intermittent asthma (95% CI, 1.340–1.486)
(Figure 5A). This was also the case for
RV-A–speciﬁc antibody signal (persistent
95% CI, 1.713–1.829; intermittent 95% CI,
1.545–1.716) (Figure 5B). RV-C–speciﬁc
antibody signal was higher in persistent
asthma in comparison with healthy control
subjects (95% CI, 1.820–1.955 vs. 95% CI,
1.577–1.753), but not in comparison with
intermittent asthma (Figure 5D). No
signiﬁcant differences were observed
between the groups in relation to RV-B
(Figure 5C). Classiﬁcation of the
participants into the three groups based on
their antibody proﬁles was also investigated
through discriminant function analysis
(see Figure E6).
RV Antibody Levels Are Not Related
to Current Asthma Control
Patients with asthma were grouped based
on disease control into controlled (n = 80)
and partially controlled/uncontrolled
(n = 81). No differences in antibody levels
were observed between controlled and
uncontrolled asthma in any RV group
(Figure 6). Patients with not-well-
controlled asthma at the time of inclusion
(95% CI, 1.478–1.604) had signiﬁcantly
higher RV antibody signal than healthy
donors (95% CI, 1.342–1.468) (Figure 6A).
The RV-A–speciﬁc antibody signal was
signiﬁcantly higher in patients with
partially controlled and uncontrolled
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Figure 2. Differential accumulation of rhinovirus (RV) species antibody signal levels between patients with asthma and healthy donors. (A) Children with
asthma have higher RV antibody signal compared with healthy donors. Patients with asthma have higher species-specific antibody signal against RV-A (B)
and RV-C (D) but not against RV-B (C). Most patients with asthma could be assigned as “high responders” against RV-A (55.2% vs. 34.3%) (E), RV-C
(60.7% vs. 35.9%) (F), and RV-A/C (56.4% vs. 32.8%) peptides (G) compared with healthy donors. Low responders: white portion of bar plot. High
responders: black portion of bar plot. Differences were significant at the 0.05 level, unpaired Student’s t test with Welch correction.
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asthma (95% CI, 1.686–1.835) than in
healthy donors (95% CI, 1.518–1.669)
(Figure 6B), and slightly increased in
children with well-controlled asthma (95%
CI, 1.637–1.764). RV-C–speciﬁc signal was
signiﬁcantly higher in partially controlled–
uncontrolled (95% CI, 1.770–1.949) and
well-controlled (95% CI, 1.777–1.931)
children with asthma than in healthy
donors (95% CI, 1.577–1.753) (Figure 6D).
No signiﬁcant differences were observed
in RV-B–speciﬁc antibody signal
(Figure 6C).
Seasonal variation in RV antibody
levels is observed only in healthy children.
The RV antibody signal was analyzed
based on the season of inclusion to the
study (Figure 7). In healthy donors,
signiﬁcant differences were observed
among children of whom samples were
obtained during summer (Figure 7A).
This variation was evident in the RV-A
(Figure 7B) and RV-C (Figure 7D)
species–speciﬁc antibody signal, but not
in RV-B (Figure 7C). No seasonal
variation was observed in antibody
levels of patients with asthma (Figures
7E–7H).
Atopic Status Does Not Affect RV
Antibody Levels
Patients with asthma were stratiﬁed as
atopic (n = 81) and nonatopic (n = 79) and
the average antibody signal per donor was
compared using Welch t test (see Figure
E7). No differences were observed between
the two groups in RV-A (A.), RV-B (D.),
and RV-C (G.) Patients were further
stratiﬁed based on the number of
previously reported LRIs (LRI = 0 and
LRI. 1). No differences were observed in
RV-A antibody levels in patients with and
without atopy with LRI = 0 (B.) and LRI. 1
(C.). No differences were observed in RV-B
antibody levels in patients with and
without atopy with LRI = 0 (E.) and LRI. 1
(F.). No differences were observed in RV-C
antibody levels in patients with and without
atopy with LRI = 0 (E.). Patients with atopy
with LRI. 1 had increased RV-C antibody
levels compared with patients without
atopy with LRI. 1 (I.). Atopy was not
related to the number of upper (ExpB =
1.046; P = 0.282) or lower (ExpB = 1.025;
P = 0.874) respiratory infections tested with
binary regression.
Discussion
This study provides several novel insights
into the RV-speciﬁc antibody repertoire of
preschool children, in both health and
asthma. 1) A clear differential of RV species
antibody levels was demonstrated in this
multinational cohort (see Figure E8), in
both health and asthma. 2) Asthma is
characterized by higher levels of antibodies
to RV-A and RV-C, but not RV-B,
suggesting differential susceptibility to these
species. 3) RV antibody levels reﬂect the
number of common colds in healthy
children, and wheeze episodes in children
with asthma. 4) In the asthma group, the
number of URIs was negatively correlated
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Figure 3. Correlation of rhinovirus (RV) antibody signal levels and reported upper respiratory tract infection (URI). RV antibody levels were linearly and
positively correlated with the number of URIs in healthy donors (A) but not in patients with asthma (E). In healthy donors, RV-A (B)–, RV-B (C)–, and RV-C
(D)–specific signal increased linearly with increasing number of URIs. In patients with asthma, none of the RV-A (F)–, RV-B (G)–, or RV-C (H)–specific signal
was correlated with the number of URIs. Differences were significant at the 0.05 level (linear regression).
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with the number of LRIs. This observation
was not affected by RV species–speciﬁc
antibody levels. 5) RV antibody levels
correlate with asthma severity but not
with current asthma control, suggesting
accumulation over longer periods of time.
6) The presence of atopy does not affect RV
antibody levels.
A newly developed technology was
used that allows the measurement of
130 different RV proteins and peptides
providing unprecedented power of analysis.
This allowed a data-driven identiﬁcation of
species-speciﬁc and mixed (cross-reactive)
antibodies using a combination of
phylogenetic and unsupervised clustering
to discriminate between expected and
observed speciﬁcity. Subsequently, RV-A,
RV-B, and RV-C species–speciﬁc peptides
were used to identify differences between
patients with asthma and healthy control
subjects.
The antibody signal follows closely
the degree of sequence homology (i.e.,
RV-A. RV-C. RV-B). Robust signal was
generated against peptides derived from the
VP1 region of all three RV species further
conﬁrming our earlier ﬁnding that the N
terminus of VP1 represents a major epitope
of RV-speciﬁc antibodies (19, 24). It has
long been thought that RV antibodies
cause a large change to the structure of the
viral coat, which neutralizes the virus and
stops infectivity (25). However, we have
shown that the viral capsid is dynamic
and undergoes uncoating when RV is
bound to ICAM-1, thus exposing the
normally inaccessible N terminus of VP1
and misdirecting the antibody response
(19, 24).
Antibody levels against RV species
were signiﬁcantly different, with RV-C .
RV-A . RV-B, in patients with asthma.
RV-A and RV-C antibodies were higher
than RV-B in healthy donors. A previous
report has suggested that total and speciﬁc
RV-A IgG1 titers are higher than both RV-B
and RV-C (17) and the species-speciﬁc
titers to RV-C are extremely low in children
with and without asthma, although they
both have high RV-C titers to cross-reactive
RV-A and RV-C antigens. Differential
detection of antibody levels against the
three RV species may be attributed to
differential exposure, differential immune
response, and the ability to analyze a
diverse repertoire of strains and epitopes.
First, RV-C species exhibit higher within-
group diversity than A and B species (9),
suggesting that exposure to a certain RV-C
strain might not inﬂuence the immune
response against other RV-C strains. This is
further supported by the lack of difference
between RV-A and RV-C in our healthy
control subjects. Second, our recent
observations associating RV-A and RV-C
antibody levels with more severe asthma
outcomes and respiratory symptomatology,
suggests a correlation of antibody response
and immune status. Finally, we have
analyzed a diverse collection of RV proteins
and peptides, with only a few overlaps with
the Iwasaki study (17) investigating
antibody levels against RV in asthma; 14
RV-A (one common: A01B), nine RV-B
(two common: B14, B69), and two RV-C
(none common).
Children with asthma have higher RV-
total and RV-A and RV-C species–speciﬁc
antibodies than healthy children without
asthma. Iwasaki and coworkers (17) also
reported similar differences (higher RV-
total, RV-A, and to a lesser extent RV-B)
when comparing antibody levels in children
with asthma during an exacerbation, with
healthy control subjects. Furthermore, we
have also previously observed increased
VP1-speciﬁc IgG1 levels in adults with
asthma (age 19–54 yr) (21). It seems that
starting from at least the preschool years,
patients with asthma develop high levels
of antibodies against speciﬁc RV species
A and C. In a responder analysis, many
more patients with asthma than healthy
participants are high responders to RV-A,
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Figure 4. Evaluation of rhinovirus (RV) antibody signal levels and reported asthma-related episodes in
patients with asthma. RV-A (B)– and RV-C (D)–specific antibody levels were linearly and positively
correlated with the number of previous wheeze episodes. No correlation was observed for the total
RV (A)- and RV-B (C)–specific antibody levels. Correlations were significant at the 0.05 level (linear
regression).
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RV-C, and RV-A/C mixed peptides. The
differential antibody response to RV
subtypes, paralleling their reported clinical
impact in asthma, and the apparent lack of
overall antibody-mediated protection from
respiratory morbidity in asthma, points
toward the innate immunity as the key
limiting factor of RV virulence (26, 27): a
defective innate response to RV-A and RV-C
in asthma may explain both the higher
levels of antibodies and increased morbidity
from these viruses (28). Indeed, it was
recently demonstrated that children,
independent of their asthma status, have a
competent CD41 T-cell recall response to
RV-A and RV-C (29).
In asthma, increased number of URIs
was correlated with decreased number of
LRIs but was not mediated by RV antibody
levels. Moreover, RV antibody levels did not
correlate with the number of URIs or LRIs as
in the healthy group. Importantly, children
with asthma reported signiﬁcantly higher
number of upper and LRIs compared with
healthy children (23). In healthy children,
RV antibody levels were robustly correlated
with the number of reported respiratory
infections in the last 12 months, in a
linear manner. Children with LRIs. 1
had signiﬁcantly lower RV-B and
slightly decreased RV-A antibody levels.
Unfortunately, the small number of LRIs
did not allow robust characterization of
URIs and LRIs and RV antibodies.
We believe that in healthy children RV
antibody accumulation is akin to the
number of RV infections and protective
from reinfection and spread to the lower
tract. Therefore, in this asthma age group,
RV antibodies accumulate without
conferring (at least clinically relevant) cross-
protection. In contrast, RV antibodies in
patients with asthma correlated with
previous wheeze episodes. This may
be caused by different kinetics of
antibody accumulation in this population
(i.e., children with asthma may have already
accumulated high levels of RV antibodies at
earlier times and are now expanding their
repertoire only after more severe infections,
associated with wheeze), and/or symptom
interpretation in children with asthma: it is
possible that several of the events identiﬁed
as URI may be in fact triggered by other
factors.
Whether patients with asthma have
more URIs than normal individuals is still
disputed, because it is possibly confounded
by different symptom thresholds in
asthmatic versus normal populations (4, 6).
It is clear, however, that people with asthma
suffer from more frequent LRIs and have
more severe and longer-lasting LRT
symptoms (30). In a cohort of younger
children sampled during an acute episode
of wheeze Stenberg-Hammar and
coworkers (18) demonstrated that more
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Figure 5. Differential levels of rhinovirus (RV) antibodies in patients with intermittent and persistent
asthma. Children with more severe asthma have higher total RV (A)- and RV-A (B)–specific antibody
levels than children with intermittent asthma. (D) RV-C–specific antibody levels were higher only in
subjects with severe asthma when compared with healthy control subjects. (C) No differences were
observed in RV-B–specific antibody levels. Differences were significant at the 0.05 level using ANOVA
with post hoc Tukey test.
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respiratory symptoms were signiﬁcantly
associated with increases in RV-A- and RV-C–
speciﬁc IgG1. Moreover, RV-B–speciﬁc
antibody levels showed a tendency to be
negatively correlated with the number of
reported LRIs in healthy participants but
not in patients with asthma, and in the
small number of healthy children that
had an LRI, RV antibody levels were
signiﬁcantly lower than those who
did not.
In consequence, RV antibodies were
also associated with asthma severity in our
cohort, with children with persistent asthma
having higher levels of RV-A and RV-C
antibodies than those with intermittent
disease. It is reasonable that patients with
more severe disease had accumulated larger
amount of RV antibodies because of a higher
number of previous infections. It should be
noted that children with severe persistent
asthma were excluded from the study. In
contrast, asthma control, reﬂecting disease
activity 1 month before the antibody
sampling, was not signiﬁcantly correlated to
RV antibody levels, even though there was a
tendency of higher RV-A and -C antibodies
in subjects with asthma with not well
controlled disease.
Seasonality was not pronounced;
however, total RV, RV-A, and RV-C
antibody levels of healthy children were at
their lowest during the summer, consistent
with the epidemiology of RVs and the
understanding of RV antibody production
kinetics (15, 31, 32). However, this was not
the case in patients with asthma suggesting
an absence of correlation between RV
antibody levels and RV epidemiology in
this age group.
Currently no models exist that can
explain how preexisting antibodies may
affect the generation of protective responses
to RV as a faction of the number of
respiratory infections and/or infecting RV
strain and if this may potentially be altered
in asthma. Our ﬁndings can be summarized
in a hypothetical graph based on the epitope
masking model (see Figure E9) (33).
Longitudinal studies, such PreDicta, are in
great need to understand the buildup and
extent of the RV antibody repertoire in
health and asthma.
The major strengths of the study are
the high number of proteins and peptides
used, the unsupervised data-driven
approach to discriminate between RV
species–speciﬁc and mixed signal, the
multicenter/multinational setting, the
narrow range of age, and the exclusion
of extreme asthma severity cases. A
limitation in this study is the retrospective
reporting of events, either infections or
wheeze episodes, which may suffer from
recall bias. However, the robustness of the
correlation between reported URI and
antibody levels in healthy children suggests
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Figure 6. Rhinovirus (RV) antibody levels in patients with asthma with different disease control. Data
are presented for RV (A)-, RV-A (B)–, RV-B (C)–, and RV-C (D)–specific peptides. Differences were
significant at the 0.05 level using ANOVA with post hoc Tukey test.
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that this is not the case, at least in this
group. Nevertheless, it is possible that the
interpretation of respiratory symptoms
in subjects with asthma, particularly in
persistent cases, is not easy and can
underpin the lack of association in this
group. In contrast, wheezing episodes are
conceivably more memorable in asthma
cases.
In conclusion, we have used the novel
PreDicta RV antibody chip to characterize
the species-speciﬁc antibody repertoire of
preschool-age children with and without
asthma. In health, RV antibodies reﬂect
previous URIs, whereas in asthma they reﬂect
previous episodes of wheeze and disease
severity. There are clear differences in RV
antibody levels between normal children
and children with asthma, and within the
asthmatic population, suggesting that these
measurements could be further explored as
potential biomarkers. The humoral immune
response to RV subgroups is variable with
higher levels of RV-C and RV-A antibodies;
however, there is no apparent protection with
increasing levels of antibodies. Longitudinal
trajectories of RV antibody levels over time,
in association with disease activity, will
provide further insights on their role in
disease progression. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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children. (E–H) Patients with asthma. RV (A), RV-A (B), and RV-C (D) antibody levels in healthy children differ between seasons. In patients with asthma, no
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